- Overcoming the Anxiety Associated with Breast Cancer Screening
- Paying Women to Have Mammograms Presents Ethical Problems
- Acupuncture Treatments Benefit Breast Cancer Survivors
- Download a Free e-Book to Reduce Your Breast Cancer Risk
- Accurately Assessing Breast Cancer Risk
- Biomarker Holds Promise for Treating Breast and Prostate Cancers
- Smoking Lowers Breast Cancer Survival Rates
- Understanding the Link Between Phthlate Exposure and Breast Cancer Risk
- Young Women with Breast Cancer Have Unique Needs
- Texts Boost Breast Cancer Screening Numbers
Vitamin D and Curcumin Could Help Clear Amyloid Beta in Alzheimer’s
The early research findings could lead to new approaches in preventing and treating Alzheimer’s by utilizing the property of vitamin D3, a form of vitamin D, both alone and together with natural or synthetic curcumin to boost the immune system in protecting the brain against amyloid beta.
Vitamin D3 is an essential nutrient for bone and immune system health; its main source is sunshine, and it is synthesized through the skin. Deficiencies may occur during winter months or in those who spend a lot of time indoors, such as Alzheimer’s patients.
“We hope that vitamin D3 and curcumin, both naturally occurring nutrients, may offer new preventive and treatment possibilities for Alzheimer’s disease,” said Dr. Milan Fiala, study author.
Using blood samples from nine Alzheimer’s patients, one patient with mild cognitive impairment and three healthy control subjects, scientists isolated monocyte cells, which transform into macrophages that act as the immune system’s clean-up crew, traveling through the brain and body and gobbling up waste products, including amyloid beta. Researchers incubated the macrophages with amyloid beta, vitamin D3 and natural or synthetic curcumin.
Researchers found that naturally occurring curcumin was not readily absorbed, that it tended to break down quickly before it could be utilized and that its potency level was low, making it less effective than the new synthetic curcuminoids.
“We think some of the novel synthetic compounds will get around the shortcomings of curcumin and improve the therapeutic efficacy,” Cashman said.
The team discovered that curcuminoids enhanced the surface binding of amyloid beta to macrophages and that vitamin D strongly stimulated the uptake and absorption of amyloid beta in macrophages in a majority of Alzheimer’s patients.
Previous research by the team demonstrated that the immune genes MGAT III and TLR-3 are associated with the immune system’s ability to better ingest amyloid beta. In this earlier work, Fiala noted, it was shown that there are two types of Alzheimer’s patients: Type 1 patients, who respond positively to curcuminoids, and Type II patients, who do not.
“Since vitamin D and curcumin work differently with the immune system, we may find that a combination of the two or each used alone may be more effective, depending on the individual patient,” he said.
Fiala noted that this is early laboratory research and that no dosage of vitamin D or curcumin can be recommended at this point. Larger vitamin D and curcumin studies with more patients are planned.
1. Milan Fiala, et al. University of California – Los Angeles.